-
MFC Industrial CEO Michael Smith Bought 180K Shares at $6.67-6.75 per Share
Monday, December 12, 2011 - 12:08pm | 66MFC Industrial Ltd. (NYSE: MIL) announced today a filing in Canada and available for inspection at www.sedar.com or www.sedi.ca, that details insider purchases of MIL shares on the open market by Chairman & CEO Michael Smith. There were two trades totaling 180,000 shares: 87,000 shares...
-
Disclosure Insight Maintains Medium Risk Rating on Luminex
Tuesday, November 29, 2011 - 7:51am | 69A report from D.I. reiterates its Medium Risk Positive Bias rating on Luminex (NASDAQ: LMNX). The report states, “Concentrated revenue supports our opinion of a Medium Risk - Positive Bias rating for LMNX. In 2010, One Lambda and Bio-Rad Laboratories accounted for 16% and 13% of total revenue,...
-
J.P. Morgan Maintains Neutral on Luminex
Wednesday, November 2, 2011 - 7:46am | 84J.P. Morgan is out with its report today on Luminex (NASDAQ: LMNX), maintaining Neutral. In its report, J.P. Morgan writes, "LMNX continues to trade at a premium valuation (on either P/Sales or P/E) to peers, and we see limited room for multiple expansion, with the potential for a slowdown in bulk...
-
A Peek Into The Market Before The Trading Starts
Tuesday, August 30, 2011 - 7:31am | 382Pre-open movers US stock futures are lower this morning, as investors are awaiting consumer confidence data and the minutes of the recent Federal Open Market Committee. Futures for the Dow Jones Industrial Average dipped 49 points to 11,468.00 and S&P 500 index futures fell 6.30 points to 1,201...
-
ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb
Tuesday, August 30, 2011 - 6:49am | 139ICON plc, (NASDAQ: ICLR) today announced that it has been chosen by Bristol-Myers Squibb Company (NYSE: BMY) as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. This latest agreement with Bristol-Myers-Squibb follows the company's selection of ICON to...
-
Top 4 Large-Cap Stocks In The Medical Instruments & Supplies Industry With The Highest Revenue
Monday, August 29, 2011 - 1:33am | 123Below are the top large-cap medical instruments & supplies stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Baxter International Inc (NYSE: BAX) is $13.54 billion. BAX's PEG ratio is 1.29. The trailing-twelve-month revenue at Thermo Fisher Scientific...
-
Top 4 Large-Cap Stocks In The Medical Instruments & Supplies Industry With The Highest Revenue
Monday, August 29, 2011 - 1:31am | 123Below are the top large-cap medical instruments & supplies stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Baxter International Inc (NYSE: BAX) is $13.54 billion. BAX's PEG ratio is 1.29. The trailing-twelve-month revenue at Thermo Fisher Scientific...
-
Auriga Maintains Buy on Thermo Fisher Scientific
Wednesday, August 24, 2011 - 8:39am | 84Auriga is out with its report today on Thermo Fisher Scientific (NYSE: TMO), maintaining Buy, after announcing the close of its Phadia acquisition. In its report, Auriga writes, "Overall, Phadia looks like another solid asset and should benefit from TMO's established global distribution channels....
-
Jefferies Has Hold On Charles River Laboratories
Wednesday, August 24, 2011 - 7:36am | 175Jefferies & Co. is out with a research report on Charles River Laboratories (NYSE: CRL) and it has a Hold rating and a $33 price target on shares. In a note to clients, Jefferies & Co. writes, "On Tuesday evening, Charles River issued a release announcing a "new business alignment" and...
-
Charles River Announces New Business Alignment; Doesn't Expect Segment Reporting Change
Tuesday, August 23, 2011 - 4:32pm | 169Charles River Laboratories International, Inc. (NYSE: CRL) announced today a new business alignment which unifies its Research Models and Services and Preclinical Services businesses. This unification will enhance our ability to provide clients with a seamless and integrated portfolio of the...
-
Notable Call Options Activity in BioDelivery Sciences International
Monday, August 22, 2011 - 10:31am | 99Shares of BioDelivery Sciences International (NASDAQ: BDSI) are higher on the session by 4.84%, currently trading at $3.25. The stock has been moving largely lower over the past two months and is currently trading below the 50-day average. Options traders are focusing on calls today. A short while...
-
Pre-Market Gainers; Pharmaceutical Product Development up 9%
Monday, August 22, 2011 - 8:36am | 74Pharmaceutical Product Development (NASDAQ: PPDI) +8.98 99 Cents Only Stores (NYSE: NDN) +8.50% on reports about a potential bid by Apollo. Williams-Sonoma (NYSE: WSM) +7.38% after positive comments by Merriman. Clearwire (NASDAQ: CLWR) +7.97% ATP Oil & Gas (NASDAQ: ATPG) +6.90%
-
Affymetrix Announces Federal Court Affirms Dismissal of Illumina Patent Infringement Lawsuits
Friday, August 19, 2011 - 6:51am | 120Affymetrix, Inc. (NASDAQ: AFFX) today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020. “We are pleased that the Federal...
-
AMRI Receives NIH Contract Award for the Development of Pre-Clinical Drug Candidates to Treat Diseases of the Nervous System
Thursday, August 18, 2011 - 4:01pm | 129AMRI (NASDAQ: AMRI) today announced it received a federal contract award from the National Institutes of Health National Institute of Neurological Disorders and Stroke to provide chemistry and other drug discovery technologies in support of NINDS' Medicinal Chemistry for Neurotherapeutics Program (...
-
SeraCare Life Sciences Expands Product Portfolio
Thursday, August 18, 2011 - 9:04am | 274SeraCare Life Sciences (NASDAQ: SRLS) today announced that the Company has introduced three new, differentiated panels to its product portfolio -- an HIV/HCV/HBV Nucleic Acid Qualification Panel, an HIV-1 RNA Linearity Panel and an Anti-HIV-2 Performance Panel. "New products play an important...